MediPharm Labs and Ace Valley Deliver Innovative Vapes - Now Available in Several Markets Across Canada

TORONTO, May 25, 2020 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that its highly anticipated and innovative suite of “Ace Valley Vapes” are officially available in several markets across Canada.   The Company shipped three new vape products under this white label brand-line to multiple provinces last week.

Ace Valley & MediPharm Labs Vapes - Now Available
Ace Valley vapes are available in CBD, Sativa and Indica and produced by MediPharm Labs using high-quality distillate.

Ace Valley & MediPharm Labs Vapes - Now Available
Ace Valley vapes are produced by MediPharm Labs using high-quality distillate free of any diluent oil in a GMP certified facility.

The launch of the Ace Valley Vapes is the culmination of the Company’s previously announced white label agreement through its subsidiary, MediPharm Labs Inc., with AV Cannabis Inc. (d/b/a Ace Valley). Through this collaboration, Ace Valley leveraged its leading brand traction and product strategy expertise to design, brand and market new and innovative vaporizer products, while MediPharm Labs provided raw material from its supply chain, high-quality cannabis distillate, formulation and filling expertise from its GMP-certified facility, as well as distribution services across Canada to cannabis distributors and retailers.

“Ace Valley has emerged as one of Canada’s true cannabis brands. We are proud to be partnering with a team that consistently raises the bar through product development and marketing ingenuity, further elevated by our superiour product formulations and top CPG-quality processes,” said Pat McCutcheon, Chief Executive Officer of MediPharm Labs.

“We are passionately building a great cannabis brand in Canada,” said Mike Wagman, Chief Executive Officer of Ace Valley. “Our new all-in-one vapes, with an innovative logo light-up feature, are a big part of our platform and we have a strong partner in MediPharm Labs, the leader in cannabis extraction and purified cannabis concentrates in Canada.”

Unique Product Formulations with Original Vape Hardware
Each Ace Valley Vape is an all-in-one unit with 0.3 ml of formulated cannabis distillate. Working in collaboration with Ace Valley, MediPharm Labs’ Applied Science team formulated three unique products - CBD, Sativa and Indica options – each comprised of 95% distillate and 5% botanically derived terpenes, with zero carrier oil, other additives, or thickening agents. Ace Valley selected this variety of vape options so consumers can curate their experience.

The vape hardware is an all-in-one unit, not requiring a separate purchase of battery and vapourizer cartridge. Ace Valley wanted to offer customers something convenient, consistent, and easy-to-use.  By providing an integrated all-in-one hardware device, they were able to deliver maximum consistency from one experience to the next, as the distillate and vapourizing hardware have been specifically designed and tested together.

“The concept for our new vapes is the brainchild of our co-founder, Noah Gill, who wanted customers to have a fun way to experience the device,” explained Mike Wagman, CEO of Ace Valley. “Unlike other vape pens on the market, the Ace Valley Vape lights up each of the four colour bands in our logo sequentially as you inhale. This provides the customer with simple and intuitive control and a unique interaction.”

Multi-Province Distribution
MediPharm Labs has already completed shipments to Ontario, BC and Alberta distribution hubs.
The Ace Valley Vapes are anticipated to be available at select retailers in ON, BC, Alberta, Manitoba, and Saskatchewan.

About Ace Valley
Ace Valley is a leading recreational cannabis brand.  Since launching in October 2018, Ace Valley has built a curated, ready-to-use portfolio of pre-rolls, vapes and real-fruit gummies* (*launching soon) with wholesale and retail distribution across most of Canada.  Ace Valley drives leading sales and brand awareness by leveraging its product strategy expertise, consumer insights and loyal community of fans.

About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, they formulate, consumer-test, process, package and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.

For further information, please contact:
Laura Lepore, VP, Investor Relations
Telephone: +1 416.913.7425 ext. 1525
Email: [email protected]
Website: www.medipharmlabs.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, expected sale of the Ace Valley Vapes at various provincial retailers. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

All information contained in this press release with respect to Ave Valley was supplied by Ace Valley for inclusion herein.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/e0e9a2f1-456e-4d74-9b83-ed4292c56ea0

https://www.globenewswire.com/NewsRoom/AttachmentNg/2795c368-8023-462a-a7ee-94d0418c39d1

medipharm logo.jpg

Source: MediPharm Labs Corp.